Sources | Names Used |
---|---|
CTRPv2 | sirolimus:bortezomib (250:1 mol/mol) |
PharmacoGx | sirolimus:bortezomib (250:1 mol/mol) |
Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SLC15A4 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
mRNA | RRNAD1 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
mRNA | ANGEL1 | CTRPv2 | pan-cancer | AAC | 0.089 | 0.01 |
mRNA | CDKN1B | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
mRNA | NAPB | CTRPv2 | pan-cancer | AAC | 0.083 | 0.01 |
mRNA | MS4A2 | CTRPv2 | pan-cancer | AAC | -0.081 | 0.01 |
mRNA | SPCS1 | CTRPv2 | pan-cancer | AAC | 0.084 | 0.01 |
mRNA | USP48 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.01 |
mRNA | GPATCH8 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
mRNA | PRELID2 | CTRPv2 | pan-cancer | AAC | -0.084 | 0.01 |